U.S. biotech funding volume suggests another record-breaking year

After an astonishing development in Q1 2021 with an increase of 106% compared to Q1 2020, the accumulated biotech venture capital funding volume still exceeds the performance of the previous year. In the 1st half of 2021, the funding volume increased by 69% compared to the first half of 2020, reaching USD 17,136m by the end of June. The largest transaction in the 2nd quarter amounted to USD 735m in Treeline Biosciences, Inc.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]